Making sense of epidemiological studies of young children exposed to thimerosal in vaccines

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1580-1586

  Dórea, José G ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Children; Ethylmercury; Infants; Neurodevelopment; Newborns; Thimerosal; Vaccines

Indexed keywords

MERCURY; METHYLMERCURY; THIOMERSAL; VACCINE;

AUTISM; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CHILD; CONCENTRATION RESPONSE; ENVIRONMENTAL EXPOSURE; HUMAN; NERVE CELL DIFFERENTIATION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW;

DEVELOPMENTAL DISABILITIES; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; NEUROTOXICITY SYNDROMES; PREGNANCY; PRESERVATIVES, PHARMACEUTICAL; THIMEROSAL; VACCINES;

EID: 77956453942     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.008     Document Type: Review

References (76)

1. Grandjean P., Landrigan P.J. Developmental neurotoxicity of industrial chemicals. Lancet 2006, 368:2167-2178.
2. Miller D.L., Ross E.M., Alderslade R., Bellman M.H., Rawson N.S. Pertussis immunisation and serious acute neurological illness in children. BMJ 1981, 282:1595-1599.
3. Ray P., Hayward J., Michelson D., et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J 2006, 25:768-773.
4. Miller E., Andrews N., Stowe J., Grant A., Waight P., Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol 2007, 165:704-709.
5. McMahon A.W., Eidex R.B., Marfin A.A., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007, 25:1727-1734.
6. Sejvar J.J., Labutta R.J., Chapman L.E., Grabenstein J.D., Iskander J., Lane J.M. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 2005, 294:2744-2750.
7. Monteiro S.A., Takano O.A., Waldman E.A. Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting. Vaccine 2010, 28:3127-3133.
8. Geier D.A., Geier M.R. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit 2005, 11:CR160-CR170.
9. Aschner M, Ceccatelli S. Are neuropathological conditions relevant to ethylmercury exposure? Neurotox Res 2009; 18:59-68.
10. Landrigan P.J. What causes autism? Exploring the environmental contribution. Curr Opin Pediatr 2010, 22:219-225.
11. Weiss B., Clarkson T.W., Simon W. Silent latency periods in methylmercury poisoning and in neurodegenerative disease. Environ Health Perspect 2002, 110(Suppl 5):851-854.
12. Counter S.A., Buchanan L.H. Mercury exposure in children: a review. Toxicol Appl Pharmacol 2004, 198:209-230.
13. Thyssen J.P., Linneberg A., Menne T., Johansen J.D. The epidemiology of contact allergy in the general population - prevalence and main findings. Contact Dermat 2007, 57:287-299.
14. Stetler H.C., Garbe P.L., Dwyer D.M., et al. Outbreaks of group A streptococcal abscesses following diphtheria-tetanus toxoid-pertussis vaccination. Pediatrics 1985, 75:299-303.
15. Puziss M., Wright G.G. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J Bacteriol 1963, 85:230-236.
16. Nelson E.A., Gottshall R.Y. Enhanced toxicity for mice of pertussis vaccines when preserved with Merthiolate. Appl Microbiol 1967, 15:590-593.
17. Seal D., Ficker L., Wright P., Andrews V. The case against thiomersal. Lancet 1991, 338:315-316.
18. Karincaoglu Y., Aki T., Erguvan-Onal R., Seyhan M. Erythema multiforme due to diphtheria-pertussis-tetanus vaccine. Pediatr Dermatol 2007, 24:334-335.
19. Halsey N.A., Goldman L. Balancing risks and benefits: primum non nocere is too simplistic. Pediatrics 2001, 108:466-467.
20. Costa L.G., Aschner M., Vitalone A., Syversen T., Soldin O.P. Developmental neuropathology of environmental agents. Annu Rev Pharmacol Toxicol 2004, 44:87-110.
21. Trasande L., Landrigan P.J., Schechter C. Public health and economic consequences of methyl mercury toxicity to the developing brain. Environ Health Perspect 2005, 113:590-596.
22. Cohen J.T., Bellinger D.C., Shaywitz B.A. A quantitative analysis of prenatal methyl mercury exposure and cognitive development. Am J Prev Med 2005, 29:353-365.
23. Palmer R.F., Blanchard S., Stein Z., Mandell D., Miller C. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place 2006, 12:203-209.
24. Palmer R.F., Blanchard S., Wood R. Proximity to point sources of environmental mercury release as a predictor of autism prevalence. Health Place 2009, 15:18-24.
25. Axelrad D.A., Bellinger D.C., Ryan L.M., Woodruff T.J. Dose-response relationship of prenatal mercury exposure and IQ: an integrative analysis of epidemiologic data. Environ Health Perspect 2007, 115:609-615.
26. Dórea J.G. Exposure to mercury during the first six months via breast milk and vaccines: modifying risk factors. Am J Perinatol 2007, 24:387-400.
27. Clarkson T.W., Vyas J.B., Ballatori N. Mechanisms of mercury disposition in the body. Am J Ind Med 2007, 50:757-764.
28. Pichichero M.E., Gentile A., Giglio N., et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 2008, 121:e208-e214.
29. Marn-Pernat A., Buturović-Ponikvar J., Logar M., Horvat M., Ponikvar R. Increased ethyl mercury load in protein a immunoadsorption. Ther Apher Dial 2005, 9:254-257.
30. Clarkson T.W., Strain J.J. Methyl mercury: loaves versus fishes. Seychelles Med Dent J 2004, 7:61-66.
31. Magos L., Clarkson T.W., Hudson A.R. The effects of dose of elemental mercury and first-pass circulation time on exhalation and organ distribution of inorganic mercury in rats. Biochim Biophys Acta 1989, 991:85-89.
32. Ceccatelli S., Daré E., Moors M. Methylmercury-induced neurotoxicity and apoptosis. Chem Biol Interact 2010, Apr 14. [Epub ahead of print].
33. Marques R.C., Dórea J.G., Fonseca M.F., Bastos W.R., Malm O. Hair mercury in breast-fed infants exposed to thimerosal-preserved vaccines. Eur J Pediatr 2007, 166:935-941.
34. Park H.J., Kim S.A., Moon J.S., Yang W., Son B.S. Mercury level in hair of primary school children in Korea and China. Mol Cell Toxicol 2008, 4:235-245.
35. Dórea JG, Wimer W, Marques, RC, Shade C. Automated speciation of mercury in hair of breastfed infants exposed to ethylmercury from thimerosal-containing vaccines. Biol Trace El Res 2010; in press (DOI:10.1007/s12011-010-8695-0).
36. Allegaert K., Van der Marel C.D., Debeer A., et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed 2004, 89:F25-F28.
37. Marques R.C., Dórea J.G., Manzatto A.G., Bernardi J.V.E., Bastos W.R., Malm O. Time of perinatal immunization, thimerosal exposure and neurodevelopment at 6months in breastfed infants. Acta Paediatr 2007, 96:864-868.
38. Dórea J.G., Marques R.C., Brandão K.G. Neonate exposure to thimerosal mercury from hepatitis B vaccines. Am J Perinatol 2009, 26:523-527.
39. Clements C.J. The evidence for the safety of thiomersal in newborn and infant vaccines. Vaccine 2004, 22:1854-1861.
40. Magos L. Neurotoxic character of thimerosal and the allometric extrapolation of adult clearance half-time to infants. J Appl Toxicol 2003, 23:263-269.
41. Stajich G.V., Lopez G.P., Harry S.W., Sexson W.R. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr 2000, 136:679-681.
42. Burbacher T.M., Shen D.D., Liberato N., Grant K.S., Cernichiari E., Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect 2005, 113:1015-1021.
43. Custodio H.M., Harari R., Gerhardsson L., Skerfving S., Broberg K. Genetic influences on the retention of inorganic mercury. Arch Environ Health 2005, 60:17-23.
44. Gundacker C., Komarnicki G., Jagiello P., et al. Glutathione-S-transferase polymorphism, metallothionein expression, and mercury levels among students in Austria. Sci Total Environ 2007, 385:37-47.
45. Dórea J.G. Breastfeeding is an essential complement to vaccination. Acta Paediatr 2009, 98:1244-1250.
46. Marques R.C., Bernardi J.V., Dórea J.G., Bastos W.R., Malm O. Principal component analysis and discrimination of variables associated with pre- and post-natal exposure to mercury. Int J Hyg Environ Health 2008, 211:606-614.
47. Verstraeten T., Davis R.L., DeStefano F., et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003, 112:1039-1048.
48. Young H.A., Geier D.A., Geier M.R. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008, 271:110-118.
49. Gallagher C., Goodman M. Hepatitis B triple series vaccine and developmental disability in US children aged 1-9years. Toxicol Environ Chem 2008, 90:997-1008.
50. Andrews N., Miller E., Grant A., Stowe J., Osborne V., Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004, 114:584-591.
51. Heron J., Golding J. ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004, 114:577-613.
52. Tozzi A.E., Bisiacchi P., Tarantino V., et al. Neuropsychological performance 10years after immunization in infancy with thimerosal-containing vaccines. Pediatrics 2009, 123:475-482.
53. Thompson W.W., Price C., Goodson B., et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10years. N Eng J Med 2007, 357:1281-1292.
54. Niu M.T., Rhodes P., Salive M., et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998, 51:503-510.
55. Li Y., Yan X.P., Chen C., Xia Y.L., Jiang Y. Human serum albumin-mercurial species interactions. J Proteome Res 2007, 6:2277-2286.
56. Niu M.T., Erwin D.E., Braun M.M. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001, 19:4627-4634.
57. Daniels J.L., Longnecker M.P., Rowland A.S. ALSPAC Study Team. Fish intake during pregnancy and early cognitive development of offspring. Epidemiology 2004, 15:394-402.
58. Hibbeln J.R., Davis J.M., Steer C., et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 2007, 369:578-615.
59. Daniels J.L., Rowland A.S., Longnecker M.P., Crawford P., Golding J. The ALSPAC Study Team. Maternal dental history, child's birth outcome and early cognitive development. Paed Per Epidemiol 2007, 21:448-457.
60. Dórea J.G. Early cognitive development and maternal dental mercury exposure: why not consider ethylmercury exposure?. Paed Per Epidemiol 2008, 22:110-111.
61. Kramer M.S. Long-term behavioral consequences of infant feeding: the limits of observational studies. J Ped 2010, 156:523-524.
62. Dórea J.G. Maternal smoking and infant feeding: breastfeeding is better and safer. Matern Child Health J 2007, 11:287-291.
63. Kelly Y.J., Watt R.G., Nazroo J.Y. Racial/ethnic differences in breastfeeding initiation and continuation in the United Kingdom and comparison with findings in the United States. Pediatrics 2006, 118:e1428-e1435.
64. Gartner L.M., Morton J., Lawrence R.A., et al. Breastfeeding and the use of human milk. Pediatrics 2005, 115:496-506.
65. Quintero Romero S., Bernal R., Barbiero C., Passamonte R., Cattaneo A. A rapid ethnographic study of breastfeeding in the North and South of Italy. Int Breastfeed J 2006, 5:1-14.
66. D'Amelio M., Ricci I., Sacco R., et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry 2005, 10:1006-1016.
67. Marques R.C., Dórea J.G., Bernardi J.V. Thimerosal exposure (from tetanus-diphtheria vaccine) during pregnancy and neurodevelopment of breastfed infants at six months. Acta Paediatr 2010, 99:934-939.
68. Marques R.C., Dórea J.G., Bernardi J.V., Bastos W.R., Malm O. Pre- and post-natal mercury exposure, breastfeeding and neurodevelopment during the first five years. Cognit Behav Neurol 2009, 22:134-141.
69. Hughes M.D., Williams P.L. Statistics and medicine: challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med 2007, 356:1705-1707.
70. Huang L.S., Myers G.J., Davidson P.W., et al. Is susceptibility to prenatal methylmercury exposure from fish consumption non-homogeneous? Tree-structured analysis for the Seychelles Child Development Study. Neurotoxicology 2007, 28:1237-1244.
71. Breithaupt A., Jacob S.E. Thimerosal and the relevance of patch-test reactions in children. Dermatitis 2008, 19:275-277.
72. Amanna I., Slifka M.K. Public fear of vaccination: separating fact from fiction. Viral Immunol 2005, 18:307-315.
73. Hanson L.A., Silfverdal S.A. Vaccination immunology. Scand J Infect Dis 2008, 40:696-701.
74. Dórea J.G. More on low-level non-occupational mercury exposure and health concerns. Sci Total Environ 2010, 408:2008-2009.
75. Shann F., Nohynek H., Scott J.A., Hesseling A., Flanagan K.L. Working Group on Nonspecific Effects of Vaccines. Randomized trials to study the nonspecific effects of vaccines in children in low-income countries. Pediatr Infect Dis J 2010, 29:457-461.
76. Madhavi Y., Puliyel J.M., Mathew J.L., Raghuram N., Phadke A., Shiva M., et al. Evidence-based National Vaccine Policy. Indian J Med Res 2010, 131:617-628.